Starting April 21, you’ll be asked to log in or sign up for a free account after viewing 10 content pages each month.
Don’t worry—creating an account is quick and easy, and it comes with added benefits! Once logged in, you’ll not only continue accessing the content you already enjoy, but you’ll also unlock exclusive features like interactive donut plots for variant protein effects and variant impacts across the gene.
Stay tuned for these updates, and thank you for being part of our community!
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | BGB-A445 |
Trade Name | |
Synonyms | BGB A445|BGBA445 |
Drug Descriptions |
BGB-A445 is an activating anti-TNFRSF4 (OX40) antibody that does not block binding to its ligand, OX40L, potentially resulting in increased immune response and anti-tumor activity (Journal for ImmunoTherapy of Cancer 2020;8:699). |
DrugClasses | OX40 Antibody 14 |
CAS Registry Number | NA |
NCIT ID | C175453 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
BGB-A445 | BGB-A445 | 0 | 1 |
BGB-A445 + Carboplatin + Tislelizumab | BGB-A445 Carboplatin Tislelizumab | 0 | 0 |
BGB-A445 + Cisplatin + Tislelizumab | BGB-A445 Cisplatin Tislelizumab | 0 | 0 |
BGB-A445 + Nab-paclitaxel + Tislelizumab | BGB-A445 Nab-paclitaxel Tislelizumab | 0 | 0 |
BGB-A445 + Paclitaxel + Tislelizumab | BGB-A445 Paclitaxel Tislelizumab | 0 | 0 |
BGB-A445 + Pemetrexed Disodium + Tislelizumab | BGB-A445 Pemetrexed Disodium Tislelizumab | 0 | 0 |
BGB-A445 + Tislelizumab | BGB-A445 Tislelizumab | 0 | 2 |